SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
- Application filed with IP Australia would expand patent estate to immunotherapy
- Creates new opportunities in the growing field of immunotherapy and reinforces a position in oncology
MELBOURNE, Australia, June 20, 2017 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today that the Company has filed a new patent application with IP Australia for oncology-related therapeutic uses of its proprietary Cymerus™ mesenchymal stem cell (MSC) technology.
The patent would cover the application of Cymerus in immunotherapy treatments, including chimeric antigen receptor T cell (CAR-T) and checkpoint inhibitor-based therapies. Cynata recently announced the filing of another patent application with IP Australia covering uses of Cymerus in oncology.
“We are thrilled to announce the filing of this patent application, which would strengthen our intellectual property portfolio in the oncology field and expand commercial opportunities for Cymerus in immunotherapy,” said Dr Ross Macdonald, Cynata’s Managing Director and Chief Executive Officer. “Immunotherapy is one of the most exciting areas in oncology and our new intellectual property ensures Cynata is well-positioned to capitalise on future growth in the field.”
About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, [email protected] Andrew Ramadge, Australia Media Contact, 0475 797 471, [email protected] Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected]
